ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea

Trial Profile

ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Acronyms ESCORT-HU
  • Most Recent Events

    • 21 Dec 2017 According to a Food and Drug administration media release, based on data from this study US FDA approved hydroxyurea for treatment of pediatric patients with sickle cell anemia.
    • 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top